Molecular interactions important for Axl activation
- Funded by The Research Council of Norway (RCN)
- Total publications:10 publications
Grant number: 311399
Grant search
Key facts
Disease
COVID-19Start & end year
20202024Known Financial Commitments (USD)
$266,328.82Funder
The Research Council of Norway (RCN)Principal Investigator
Endre KjærlandResearch Location
NorwayLead Research Institution
BERGENBIO ASAResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
AXL is a receptor tyrosine kinase that is highly expressed in several cancers, and activation of AXL is associated with cell survival, proliferation, migration and immunological response. Because AXL is involved in many cellular processes across different malignant tissue types, there is a critical need to understand and modulate Axl signaling in the tumor microenvironment. The aim of this project is to improve the understanding of the molecular mechanism of the interaction between AXL and GAS6, PtdSer, and the therapeutic antibody tilvestamab by using structural biology as a research method. The methods used are cryo-electron microscopy and X-ray crystallography. After the global Covid pandemic had started, AXL was identified as a possible binding partner of the spike protein of COVID-19. A collaboration with Professor Wendy Maury at the Universitiy of Iowa confirmed that AXL mediates an increase in COVID-19 infection. This project also showed that the mechanism is not through a direct interaction with the spike protein, but rather an interaction with a lipid in the viral membrane. These results are now part of a publication in the journal PLoS Pathogens.
Publicationslinked via Europe PMC
Last Updated:39 minutes ago
View all publications at Europe PMC